Motus GI Reports Third Quarter 2022 Financial Results and Provides Business Update

• Pure-Vu EVS approved for use at 25 hospitals since launch in March 2022, resulting in highest quarterly revenue reported in the Company's history
  
  
  
  
• Recently named a Sole Source Supplier by the Department of Veteran's Affairs, with several VA medical centers executing new contracts for Pure-Vu EVS systems under this designation
  
  
  
  
• Presented positive clinical data in three abstracts at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting that further illustrate how Pure-Vu EVS is enabling physicians to significantly improve visualization during colonoscopy procedures across different settings and patient populations

FORT LAUDERDALE, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the third quarter ended September 30, 2022 and provided a corporate update.

"We reported revenue in the third quarter of $278,000, which represents an approximately 50% increase compared with the second quarter of 2022, and our highest quarterly revenue to date. We continue to drive steady quarterly growth since our launch of Pure-Vu EVS six months ago. We believe our results are driven by an expanded commercial footprint and the positive attributes of the Pure-Vu EVS system," commented Tim Moran, Chief Executive Officer. "There are approximately 25 hospitals with our system in place, which includes a balanced mix of academic, community, and VA hospitals. While the third quarter represented a solid performance, we did see a few accounts push their purchasing decision to the fourth quarter, which we believe is mainly due to capital budget constraints and continued hospital staffing challenges."

"Now that we have established a solid base of hospitals with Pure-Vu EVS in use, we are incentivizing our sales team to increase the quarter-on-quarter utilization of Pure-Vu EVS disposable sleeves within each account. We believe that driving consistent repeat utilization is key to our long-term growth and is expected to generate predictable, sustained revenues. Our plan is aimed at going deeper in each metro market, while also strategically expanding to new hospitals," added Mr. Moran.

 Third Quarter and Recent Business Highlights

	Nearly doubled the initial guidance of hospital placements for Pure-Vu EVS, with 25 hospitals currently approved, approximately six months since launch. Successful commercial program for the Pure-Vu EVS System continues to drive steady revenue growth, which resulted in highest quarterly revenue in the Company's history. Commercial strategy aimed at increasing levels of utilization within existing accounts while strategically expanding to new hospitals. Driving utilization of disposable sleeves is key to the Company's long-term success as it can provide predictable, recurring, and sustained revenue growth.
Clinical Data Generation
	In October, the Company presented three abstracts featuring positive new clinical data on the Pure-Vu EVS in poster sessions during the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting. These three presentations showcase how the Pure-Vu System enables physicians to significantly improve visualization during colonoscopy procedures for patients with inadequate bowel preparation across different settings and patient populations.
Outpatient Reimbursement Strategy
	Continue advancing a multi-pronged strategy to secure reimbursement for the Pure-Vu System procedure by both private and public payers that could accelerate use for certain outpatient colonoscopies, within a market representing approximately 4.7 million targeted outpatient procedures per year. The Company is preparing to initiate a large, multi-center trial designed to show a significant reduction in the number of aborted or poor-quality exams that lead to an early repeat procedure as defined by the Gastroenterology Tri-Society guidelines. The study's aim is to generate data quantifying the percentage of patients with inadequate prep and showing the Pure Vu Systems ability to achieve a substantial clinical improvement in those patients compared to the standard of care in a large multicenter trial. The results from this study are expected to support applications seeking reimbursement of the Pure-Vu System when used in certain outpatient colonoscopies.
Product Innovation
	On track to launch the Pure Vu EVS Gastro device in the U.S. market in 2023. This device will bring upper GI capabilities to the new Pure-Vu EVS platform through key enhancements, including a larger and more powerful suction channel, more efficient irrigation jets, and a smaller profile distal tip that offers enhanced flexibility during insertion. Upper GI bleeds occurred in the U.S. at a rate of approximately 400,000 cases per year in 2019, according to iData Research Inc. The existence of blood and blood clots in these patients can impair a physician's view, making it difficult to identify the bleed source. Motus believes removing adherent blood clots from the field of view is a significant need in allowing a physician the ability to identify and treat the bleed source. The mortality rate of this condition can reach up to approximately 13%, as noted in Thad Wilkins, MD, et al., American Family Physician (2012).
Strategic Partnerships & Collaborations
	The Company continues to pursue various opportunities with strategic partners both in and outside of the U.S. The Company believes the success it's had with the commercial program for the Pure-Vu EVS should provide potential opportunities. The Company's focus in evaluating these opportunities is centered upon accelerating its commercial progress and potentially strengthening its balance sheet.

Financial Results for the Third Quarter Ended September 30, 2022

The Company reported revenue of $278,000 for the third quarter 2022, compared to $141,000 for the same period last year. Revenues for this past quarter also represented an approximately 50% increase over the second quarter 2022 and were primarily derived from reorders and new customer orders of disposable sleeves, as well as limited workstation sales and rentals.

For the three months ended September 30, 2022, the Company reported a net loss attributable to common shareholders of $5.0 million, or $1.69 per basic and diluted share, compared to a net loss attributable to common shareholders of $4.8 million, or $2.00 per basic and diluted share, for the same period last year.

During the third quarter 2022, net cash used in operating activities and for the purchase of fixed assets was $3.8 million compared to $3.1 million for the same period of 2021.

The Company reported $13.3 million in cash and cash equivalents as of September 30, 2022. This balance includes the fully funded credit facility with Kreos Capital. After the third quarter end, the Company sold approximately $5.5 million worth of shares from its existing at-the-market facility. As a result, the Company's current cash balance allows it to meet anticipated needs through the second quarter 2023.

Motus GI Holdings, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets Highlights

(unaudited, in thousands)

		As of
		September 30, 2022			December 31, 2021
Cash		$	13,294		$	22,563
Working capital			10,020			20,629
Total assets			17,366			26,089
Total shareholders' equity			762			9,657

Conference Call:

The Motus GI management team has scheduled a conference call for today, November 14th, at 4:30 p.m. ET to discuss these results. To access the conference call, investors are invited to dial (877) 407-0792 (U.S. and Canada) or (201) 689-8263 (International). The conference ID number is 13733811. A live audio webcast can be accessed by visiting the investor relations section of the Company's website, www.motusgi.com or (click here). A replay of the webcast will be archived on the Motus GI website for 90 days following the event.

About Motus GI

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms, including without limitation, risks related to the continued impact of the COVID-19 pandemic, risks inherent in the development and commercialization of potential products, possible or assumed future results of operations, business strategies, potential grow opportunities, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company's quarterly and annual reports filed with the Securities and Exchange Commission, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:

Troy Williams

LifeSci Advisors

(518) 221-0106

[email protected]

Motus GI Holdings, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	September 30,				December 31,
	2022				2021
		(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	13,294			$	22,563
Accounts receivable		161				109
Inventory		1,014				496
Prepaid expenses and other current assets		1,018				793
Total current assets		15,487				23,961
Fixed assets, net		1,395				1,428
Right-of-use assets		471				687
Other non-current assets		13				13
Total assets	$	17,366			$	26,089
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable and accrued expenses	$	2,696			$	2,584
Operating lease liabilities - current		248				307
Other current liabilities		70				10
Current portion of long-term debt, net of unamortized debt discount of $260 and $271, respectively		2,453				431
Total current liabilities		5,467				3,332
Contingent royalty obligation		1,789				1,760
Operating lease liabilities - non-current		220				385
Convertible note, net of unamortized debt discount of $123 and $166, respectively		3,877				3,834
Long-term debt, net of unamortized debt discount of $176 and $317, respectively		5,251				7,121
Total liabilities		16,604				16,432
Commitments and contingent liabilities (Note 9)
Shareholders' equity
Common stock $0.0001 par value; 115,000,000 shares authorized; 3,025,502 and 2,416,021 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively		-				-
Additional paid-in capital		138,431				132,411
Accumulated deficit		(137,669	)			(122,754	)
Total shareholders' equity		762				9,657
Total liabilities and shareholders' equity	$	17,366			$	26,089

Motus GI Holdings, Inc. and Subsidiaries

Condensed Consolidated Statements of Comprehensive Loss

(unaudited, in thousands, except share and per share amounts)

	Three Months Ended September 30,								Nine months Ended September 30,
	2022				2021				2022				2021
Revenue	$	278			$	141			$	483			$	292
Operating expenses:
Cost of revenue - sales		83				65				166				135
Cost of revenue - impairment of inventory		-				186				159				186
Research and development		1,573				1,187				4,261				4,040
Sales and marketing		1,349				725				3,554				2,196
General and administrative		1,978				2,315				6,167				7,104
Total costs and expenses		4,983				4,478				14,307				13,661
Operating loss		(4,705	)			(4,337	)			(13,824	)			(13,369	)
Gain (loss) on change in estimated fair value of contingent royalty obligation		34				(35	)			(29	)			(152	)
Loss on extinguishment of debt		-				(237	)			-				(237	)
Finance expense, net		(310	)			(216	)			(1,001	)			(450	)
Other income		-				5				-				5
Foreign currency gain (loss)		17				(4	)			(61	)			(12	)
Net loss		(4,964	)			(4,824	)			(14,915	)			(14,215	)
Deemed dividends from warrant issuance		-				-				-				(6,145	)
Net loss attributable to common shareholders	$	(4,964	)		$	(4,824	)		$	(14,915	)		$	(20,360	)
Basic and diluted loss per common share:
Net loss attributable to common shareholders	$	(1.69	)		$	(2.00	)		$	(5.40	)		$	(8.77	)
Weighted average number of common shares outstanding, basic and diluted		2,937,530				2,412,059				2,763,164				2,320,982